Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (r)-p-camps
2. (rp)-camps
3. 3,5'-camps
4. Adenosine 3',5'-cyclic Monophosphorothioate
5. Adenosine 3',5'-monothionophosphate
6. Adenosine-3',5'-cyclic Phosphorothioate
7. Adenosine-3',5'-monophosphorothioate
8. Cyclic Adenosine 3,'5'-phosphorothioate
9. Cyclic Apt
10. P-adenosine 3',5'-cyclic Phosphorothiate
11. R(p)-camps
12. Rp-camp-s
13. Sp-camp-s
1. (rp)-camps
2. Cyclic Apt
3. Rp-camps
4. Adenosine-3',5'-cyclic Phosphorothioate
5. 23645-17-2
6. (sp)-camps
7. Chebi:84615
8. Chebi:84622
9. Adenosine-3',5'-cyclic -monophosphorothioate
10. 71774-13-5
11. Rp-camp-s
12. Sp-camp-s
13. (r)-p-camps
14. 3,5'-camps
15. Sp-adenosine-3',5'-cyclic-monophosphorothioate
16. Rp-adenosine 3',5'-cyclic Monophosphorothioate, Sodium Salt
17. R(p)-camps
18. Adenosine 3',5'-monothionophosphate
19. Adenosine-3',5'-monophosphorothioate
20. 6-(6-amino-purin-9-yl)-2-thioxo-tetrahydro-2-furo[3,2-d][1,3,2]dioxaphosphinine-2,7-diol
21. Cyclic Adenosine 3,'5'-phosphorothioate
22. P-adenosine 3',5'-cyclic Phosphorothiate
23. Adenosine 3',5'-cyclic Monophosphorothioate
24. 73208-40-9
25. Adenosine, Cyclic 3',5'-(hydrogen Phosphorothioate)
26. Gtpl5262
27. Schembl4159569
28. Chembl1235719
29. Chembl1236010
30. Schembl22370431
31. Dtxsid20178316
32. Chebi:191063
33. Adenosine 3',5'-thiophosphoric Acid
34. Db01790
35. Hy-100530a
36. Hy-100530b
37. Ncgc00182722-01
38. Ncgc00485585-01
39. (4ar,6r,7r,7as)-6-(6-aminopurin-9-yl)-2-hydroxy-2-sulfanylidene-4a,6,7,7a-tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinin-7-ol
40. Cs-0019676
41. Cs-0107084
42. (rp)-adenosine-3',5'-cyclic Monophosphorothioate
43. (sp)-adenosine-3',5'-cyclic Monophosphorothioate
44. Q27088619
45. Q27157921
46. Rp-adenosine-3',5'-cyclic-monophosphorothioate
47. Adenosine-3',5'-cyclic Monophosphorothioate, Rp-isomer
48. Adenosine-3',5'-cyclic Monophosphorothioate, Sp-isomer
49. Adenosine, Cyclic 3',5'-[hydrogen [p(s)]-phosphorothioate]
50. Adenosine- 3', 5'- Cyclic Monophosphorothioate, Rp- Isomer
51. (2r,4ar,6r,7r,7as)-6-(6-amino-9h-purin-9-yl)-7-hydroxy-2-sulfanyltetrahydro-2h,4h-2lambda(5)-furo[3,2-d][1,3,2]dioxaphosphinin-2-one
52. (2r,4ar,6r,7r,7as)-6-(6-amino-9h-purin-9-yl)tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinine-2,7-diol 2-sulfide
53. (2s,4ar,6r,7r,7as)-6-(6-amino-9h-purin-9-yl)-7-hydroxy-2-sulfanyltetrahydro-2h,4h-2lambda(5)-furo[3,2-d][1,3,2]dioxaphosphinin-2-one
54. (2s,4ar,6r,7r,7as)-6-(6-amino-9h-purin-9-yl)tetrahydro-4h-furo[3,2-d][1,3,2]dioxaphosphinine-2,7-diol 2-sulfide
55. (4ar,6r,7r,7as)-6-(6-aminopurin-9-yl)-2-hydroxy-2-sulanylidene-4a,6,7,7a-tetrahydro-4h-uro[3,2-d][1,3,2]dioxaphosphinin-7-ol
56. Rp1
Molecular Weight | 345.27 g/mol |
---|---|
Molecular Formula | C10H12N5O5PS |
XLogP3 | -0.8 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 10 |
Rotatable Bond Count | 1 |
Exact Mass | 345.02967667 g/mol |
Monoisotopic Mass | 345.02967667 g/mol |
Topological Polar Surface Area | 170 Ų |
Heavy Atom Count | 22 |
Formal Charge | 0 |
Complexity | 502 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Protein Kinase Inhibitors
Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)
ABOUT THIS PAGE
A RP1 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of RP1, including repackagers and relabelers. The FDA regulates RP1 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. RP1 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A RP1 supplier is an individual or a company that provides RP1 active pharmaceutical ingredient (API) or RP1 finished formulations upon request. The RP1 suppliers may include RP1 API manufacturers, exporters, distributors and traders.
RP1 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of RP1 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right RP1 GMP manufacturer or RP1 GMP API supplier for your needs.
A RP1 CoA (Certificate of Analysis) is a formal document that attests to RP1's compliance with RP1 specifications and serves as a tool for batch-level quality control.
RP1 CoA mostly includes findings from lab analyses of a specific batch. For each RP1 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
RP1 may be tested according to a variety of international standards, such as European Pharmacopoeia (RP1 EP), RP1 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (RP1 USP).
LOOKING FOR A SUPPLIER?